Lightnews — Scholar-powered news

Reposted by Brendon Neuen

Joel Topf @kidneyboy.bsky.social · 15d

Interesting slide #BucketOfColdWater

Brendon Neuen @brendonneuen.bsky.social · 27d

📢 New in CJASN: pooled analysis of all completed phase 2/3 RCTs in #IgAN

🔹 4 drug classes (steroids, B-cell, complement, non-immunological)
🔹 All ↓ proteinuria ≥30%
🔹 All improved GFR slope
🔹 Biggest benefit: B-cell therapies

journals.lww.com/cjasn/abstra...

4

Reposted by Brendon Neuen

Nephrology Journal Club @nephjc.bsky.social · Sep 3

If you want to support #NephJC and get some cool merch, check out
www.nephjc.com/merch...

3 3

Reposted by Brendon Neuen

Nephrology Times @nephtimes.bsky.social · Aug 22

Attending Kidney Week 2025? Check out details about the plenaries. We'll be there, at Booth 2234! #kidneywk #nephrology #nephsky @asnkidney.bsky.social www.docwirenews.com/post/asn-rev...

ASN Reveals Kidney Week Plenary Details | Docwire News

The American Society of Nephrology announced details of the plenary sessions scheduled to take place at Kidney Week 2025, which will take place November 6-9, in Houston, Texas.

www.docwirenews.com

1

Reposted by Brendon Neuen

ISNkidneycare @theisn.org · Aug 21

Your abstract could be next to inspire change in kidney care. When you share your research at #ISNWCN, the benefits go far beyond the presentation.
• Global visibility
• Peer recognition
• Publication opportunity

Submit your abstract today ➡️ http://lite.spr.ly/6...

3 2

Reposted by Brendon Neuen

Nephrology Journal Club @nephjc.bsky.social · Aug 5

😎Check out the VA for HiLO by @sejalplakhani.bsky.social
🆒 This should be quite the discussion, don't miss it!
#NephJC #NephSky
www.nephjc.com/news/2025/8/4/the-hilo-trial-visual-abstract

The HiLo Trial - Visual Abstract — NephJC

Is a lower versus higher phosphate target beneficial to patients undergoing hemodialysis? Check out this crisp VA by Dr Sejal Lakhani

www.nephjc.com

13 16

Brendon Neuen @brendonneuen.bsky.social · Jul 15

Reduction in all-cause hospitalisation driven by fewer admissions for:
- Cardiac
- Renal
- Metabolic disorders, and
- Infections

Interestingly reduction in infections also observed with semaglutide in the FLOW trial - could GDMT improve physical resilience & susceptibility to infections?

1 2

Reposted by Brendon Neuen

ISNkidneycare @theisn.org · Jul 15

🌏 Join us at WCN'26 in Yokohama!
🧠 Learn from global experts
📈 Share your research
👥 Connect with peers
📅 Abstracts due Oct 22
🎬 #ISNFilmEvent submissions by Nov 5
✈️ Travel grants & registration open Sept 16
🔗 http://lite.spr.ly/6... #ISNWCN

3 1

Brendon Neuen @brendonneuen.bsky.social · Jul 15

SGLT2i in CKD: impact beyond kidneys

🔻 15% all-cause hospitalizations
✅ Consistent regardless of eGFR, UACR & diabetes
🏥 ~36 fewer hospitalizations per 1000 pt-years

Large absolute gains for patients & health systems

Meta-analysis in @asnpublications.bsky.social

journals.lww.com/cjasn/pages/...

1 10 13

Brendon Neuen @brendonneuen.bsky.social · Jul 9

Good example of CV and kidney co primary outcome

1 1 3

Brendon Neuen @brendonneuen.bsky.social · Jul 9

Yeah I think that is the one way and probably the right approach, similar to what HF has done - ideally large enough numbers of patients receiving each component of GDMT #nephjc

1 1

Brendon Neuen @brendonneuen.bsky.social · Jul 9

Yep I'm not talking in the context of this study. I just need to pick the occasional argument with @kidneyboy.bsky.social to keep it interesting 😉 #nephjc

2 5

Brendon Neuen @brendonneuen.bsky.social · Jul 9

No denial to GDMT. Patients should be as well treated as possible, and then evaluate new therapies vs placebo on top of that. Mandating everyone is on RASi/SGLT2i/MRA/GLP-1 may reduce generalisability, as not all patients will tolerate or can access all 4 drugs

1 1 5

Brendon Neuen @brendonneuen.bsky.social · Jul 9

A super complicated topic - one worth discussing in detail. I'm not sure the answer is as simple as ditching placebo. One of the advantages is it allows us to better evaluate safety of new therapies, and incremental benefits on top of real-world SoC - which varies widely around the world #nephjc

3 7

Brendon Neuen @brendonneuen.bsky.social · Jul 9

Or alternative endpoints such as hierarchical composite endpoints that may increase statistical power to detect treatment effects, incorporating both clinical outcomes (dialysis, 2xSCr etc) and intermediate endpoints (GFR slope)

1

Reposted by Brendon Neuen

Christos Argyropoulos MD, PhD, FASN 🇺🇸 0kale/acc @christosargyrop.bsky.social · Jul 9

Only reason to sequence the RASi first is that they are good antihypertensives (but note the BP effect in the combo arm of #confidence) #nephjc

But no matter the sequence, the goal should be to have someone on the four pillars in less than 6 months

1 6 11

Brendon Neuen @brendonneuen.bsky.social · Jul 9

@nephjc.bsky.social joining late, hi everyone 👋

nephrologist in Sydney, exec committee member of FIND-CKD, consult to both BI and Bayer and a number of other similar companies

1 1 5

Brendon Neuen @brendonneuen.bsky.social · Jul 9

UACR<30, less than 1ml/min/yr decline, or G1/2 A1!

3

Reposted by Brendon Neuen

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · Jul 8

Check out the Kidney Compass 🎙️ from @brendonneuen.bsky.social and Shikha Wadhwani with Rajiv Agarwal on CONFIDENCE

podcasts.apple.com/ca/podcast/k...

Prep for #NephJC tonight

CONFIDENCE Trial at ERA 2025, with Rajiv Agarwal, MD, MS

Podcast Episode · Kidney Compass: Navigating Clinical Trials · 2025-06-06 · 22m

podcasts.apple.com

2 6

Reposted by Brendon Neuen

Kidney International @kidneyint.bsky.social · Jul 7

Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Assessing the Efficacy and Safety of Felzartamab for IgA Nephropathy

doi.org/10.1016/j.kint.2025.05.028

#OpenAccess #IgAN #felzartamab #IgANephropathy

7 7

Reposted by Brendon Neuen

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · Jul 7

Following on CONFIDENCE (on #NephJC tomorrow)

The design and baseline data from MIRO-CKD trial

academic.oup.com/ndt/advance-...

N = 614, balcinerone, dapagliflozin
Urine ACR outcome

#NephSky

3 8

Reposted by Brendon Neuen

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · Jul 2

We don’t get to discuss every important study that comes out on #NephJC

Hence #NephJCShorts

www.nephjc.com/news/nephjc-...

Introducing NephJC Shorts — NephJC

In just over a decade of critical appraisal on NephJC, we have done several experiments. Some of them have worked out phenomenally well, such as the Freely Filtered podcast. Others were not ready for ...

www.nephjc.com

1 9 15

Reposted by Brendon Neuen

Nephrology Journal Club @nephjc.bsky.social · Jul 2

The #NephJC editorial team knows that plenty of papers deserve attention between our bi-monthly, full-length discussions

✨Enter #NephJCShorts - quick hits with a critical eye 🦅 on high-impact reads
www.nephjc.com/news/nephjc-...

#MedSky #NephSky

Introducing NephJC Shorts — NephJC

In just over a decade of critical appraisal on NephJC, we have done several experiments. Some of them have worked out phenomenally well, such as the Freely Filtered podcast. Others were not ready for ...

www.nephjc.com

10 11

Reposted by Brendon Neuen

Michelle Rheault, MD @rheaultm.bsky.social · Jun 22

From Rivka Galchen’s article in @newyorker.com:

“The kidney, a tremendously under-celebrated organ, basically does four-dimensional sudoku with ions.”

And that’s how I’m going to explain it from now on.

“The kidney, a tremendously under-celebrated organ, basically does four-dimensional sudoku with ions.”

1 9 36

Brendon Neuen @brendonneuen.bsky.social · Jun 11

Very helpful. Thanks Michelle #nephjc

2